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Examination of endocrine disruptor effects in neuroendocrine systems in vivo and in vitro 
 
The effects of environmental loads (physical, chemical, biological) interfere with human 
homeostatic psycho-neuroendocrine-immune mechanisms. Clarifying the role of the triggered 
effects and their impact factors became an acute task for the 21st century. The aim of the present 
study was to investigate the effects of chemical (aromatic/halogenated hydrocarbons) and 
physical (extreme low frequency and dose electromagnetic fields: ELF-EMF) environmental 
loads as endocrine disruptors (ED). In addition, we have investigated the role of these factors 
in cell and individual exposure to clarify the mechanisms induced. We considered it particularly 
important to study the relationship between indirect and direct effects in cell transformation 
events associated with endocrine regulatory disorders.  
In our work, we developed in vivo (Wistar rat chlorobenzene treatment through gastric tube; ♀ 
Wistar rats treatment by subcutaneous estrogen implantation; treatment of turkey with ELF- 
EMF), and in vitro (neurohypophysis, adenohypophysis monolayer cell culture) exposure 
models and standardized them for general viability and/or specific functional attractors 
(mechanism cycles). 
The chemical agents tested were hexachlorobenzene: 1,2,4-trichlorobenzene = 1:1 (mClB); 1,4-
dichlorobenzene (dClB); phenuron (PU), monuron (MU) and diuron (DU) as ED investigated 
for dose and time dependence). It has been found that said agents have ED effects on OT, AVP, 
ACTH and PRL release. Furthermore, we have determined the human toxicity potential (HTP) 
values for dClB in the chemical exposures studied.  
We have demonstrated that ELF-EMF is a cellular ED which modifies the functions of cell 
membrane receptors (G proteins) involved in regulatory mechanisms. We developed an 
adenohypophyseal prolactinoma (PRLOMA) model by estrogen stimulation through a positive 
feed-back mechanism. We have experimentally demonstrated that the functional derangement 
of the PRLOMA-like adenohypophysis with ED agents often triggers a non-compensable event 
cascade when compared to normal cell function.  
Based on our in vitro results, we also investigated the role of ED effects in the background of 
thyroid cell transformation disorders diagnosed in medical practice. We found a correlation 
between ED exposures and anti-TG or anti-TPO-labeled thyroid malignant tumors, 
respectively. Our findings reveal that mClB, PU, MU, DU, and ELF-EMF can be regarded as 
ED. In addition, we have demonstrated that chronic endocrine regulatory disorders may induce 
cell transformation so that the target cells of which show different behavior in their regulation 
compared to healthy cells. We have found a relationship between the real thyroid cell 
transformations (malignant tumors), the presence of anti-TG/anti-TPO markers and EDs in the 
medical histories of the patients. 
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1. Introduction 
1.1 The environment and the endocrine system  
 
Over the last few decades, nearly 100,000 artificial molecules have been introduced into 
everyday use in our society through chemization, affecting the functionality of the psycho-
neuro-endocrine-immune system, i.e. influencing the maintenance of homeostasis. This is 
an environmental burden through the use of soil, air, water, food and consumer products. 
Exposure should be explored in terms of duration, volume, cumulative risk for social, 
economic, geographical, occupational, genetic and health factors (1). While medicinal 
products for human use are subjected to extensive human in vitro and in vivo toxicity studies 
for the approval procedure, even limited human and/or eco-toxicological, etc. effects studies 
are seldom required for the application of already existing or newly synthesized chemicals, 
even though these substances may contaminate the environment directly as well as 
indirectly (2). During exposure, the concentrations of the chemicals as well as the duration 
of the effects and their presence in the human life cycle are all important factors. The most 
critical time-span is the prenatal period for the development of abnormal hormonal 
imprinting (early effect is more persistent), but the years of early childhood are also highly 
sensitive (3). Physiological and structural alterations induced by the chronic presence of 
specific chemicals, are the results of epigenetic changes, which, like mutations, may be 
passed on from one generation to the next (4). The resultant of the exposure to the given 
chemicals may be modified by the length of their biodegradation time, together with a 
combination of several external chemical factors, as well as the chronic presence of a low 
dose (5). The peripheral essential functions of the neuroendocrine system are predominantly 
mediated by the hormones of the adrenal cortex and the thyroid, any changes in their 
function may lead to essential pathophysiological events (6, 7). The endocrine system is 
involved in the coordination of cell functions not only through the direct effects of 
hormones, but also through ionic milieu, for example the regulation of calcium level by the 
parathyroid gland (8). Chemical agents are not the only culprits causing endocrine function 
disorders, changes of physical energy transmission (electromagnetic fields (EMF)) can do 
the same (9). The agents that generate endocrine disruption are called endocrine disruptors 
(ED). ED effects at the effectorial (cellular) level interfere with the physiological bases of 
the binding between the specific receptor and its hormone due to external environmental 
factors. By classifying the interfering effects mentioned, the following mechanisms can be 
distinguished according to the pathways involved in mediating the ED effects: 
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- the endocrine disruptor compounds (EDC) may bind to the receptor, which interferes with 
the normal transduction (e.g. in space, time), thus causing an atypical response.  
An EMF factor can also cause similar results; 
- the factors (chemicals, EMF) interacting with the receptor do not induce activity but inhibit 
physiological hormone binding, which consequently obstructs the endocrine response to be 
regulated; 
- modifying the transport of specific hormones by interfering with the transport protein 
function (EDC, EMF effects); 
- ED factors may interfere structurally and functionally with the enzyme pool of hormone 
synthesis (e.g. binding and/or biochemical transformation of specific hormones); 
- ED effects may interfere with the expression of specific hormone receptors  
(5, 10, 11, 12, 13). The mechanisms outlined above may play a role in obesity, diabetes 
mellitus, cardiovascular diseases, male and female reproductive abnormalities, hormone 
sensitive tumors (in women: breast, ovarian, endometrial, in males: prostate), thyroid 
diseases, neuro-developmental disorders (14, 15). 
 
1.2 The environment and the thyroid (diseases, cancer, medical history) 
 
Environmental factors can alter thyroid function in many ways. Such a mechanism may be 
brought about through the modulation of the binding process of thyroid hormones and 
thyroid-stimulating hormone (TSH) to the receptor; formation of autoantibodies blocking 
thyroid function, inhibition of iodine uptake; interfering with binding to hormone 
transporting proteins, altering thyroid hormone synthesis; inhibition of deiodinase enzyme; 
or direct thyroid damaging effect (16, 17). The outlined factors appear not only in the 
development of various functional disorders (e.g. thyroid dysfunction, autoimmune thyroid 
diseases), but also in the development of a significantly increasing number of thyroid 
carcinomas in the last few decades (18). In an animal model, the decrease in thyroid 
hormone production and the consequently elevated level of TSH can lead to the 
development of thyroid tumors (hypertrophy, hyperplasia, adenoma, carcinoma) (19, 20). 
In humans, higher TSH levels may have also thyroid cell transformation inducing activity 
(21, 22) and there are data between the connection with autoimmune thyroid disease 
(Hashimoto’s thyroiditis) and thyroid cancer (23, 24). Recognizing the relationship between 
exposure to the environment and the illness it creates is not easy, because of the long latency 
(up to several decades), and therefore, thorough history taking during the medical 
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examination can provide important information from this aspect as well. Only few data are 
available for thyroid carcinomas associated with proven ED effect (25, 26). 
 
1.3 Effects of Endocrine Disruptors (regulatory disturbances, ionic milieu, 
homeostasis) 
 
Increasing number of physical and chemical burdens have triggered environmental health 
risks (27) and have become known as ED effects (chemical (EDC) and physical (EMF)). 
ED exposures generate changes at the level of the organism, affecting e.g. the human 
homeostatic complexity. They may alter the potential of the psycho-neuro-endocrine-
immune regulation network (10), its capacity (28), and may bring about changes leading to 
regulatory disturbances. These effects may be a heavy homeostatic regulatory burden even 
in young healthy individuals, but in elderly healthy people they may cause changes really 
difficult to compensate for (29). The human adaptation patterns induced by environmental 
burdens are obviously more characteristic when the exposure takes place while some 
functional and/or structural disorder is also present (30). An open dynamic system (such as 
a living human organism) is able to maintain equilibrium with its direct environmental 
conditions by the aid of its genetic and functional adaptation potential (31). Hormones are 
creative elements of the neuroendocrine regulation in the human homeostasis (32). In 
neuroendocrine regulation, peripheral endocrine functions are maintained by neuronal and 
hormonal control (33). In the outlined context, human neuroendocrine regulation can be 
interpreted as a network of open, dynamic biological systems. This is accomplished by the 
human body via ensuring its essential processes, ionic milieu, pH balance, volume control, 
osmolality requirements and appropriate partial O2/CO2 tensions, etc. which are regulated 
parallel in n dimensions [- located in space and continuous in time -]. So if an ED effect 
disrupts the ionic balance (e.g. adrenal, pituitary, parathyroid disorders), other homeostatic 
regulatory elements need to change their processes with immediate compensatory 
mechanisms because maintaining homeostasis is sine qua non of healthy life and adaptation 
itself. In the maintenance of healthy, general cellular functions, the extracellular 
concentrations of the monovalent Na+/K+ and the bivalent of Ca2+/Mg2+ cations may be of 
particular importance in ED effects (34, 35), as they have vital roles in the regulation of 
membrane potential, ionic balance, extra- and intracellular transductions and information 
transmission, energy balance, exocytosis, synthesis processes, etc. The study of effects in 
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connection with electric energy usage (EMF effects as ED effects) is markedly interesting, 
as this is essential in the use of energy for humans. The membrane potential of cells is 
controlled by the homeostatically maintained inequal distribution of ions. This is the 
electrical and magnetic space maintained in the living system which clearly changes when 
utilizing other forms of energy (extra environmental load) in EMF (which can be interpreted 
as electrosmog). In an altered EMF background, the orientation, movement of the dipoles, 
the expression and/or functional security of the receptors may undergo vast changes. All 
these can obviously generate ED effects (e.g. breast cancer, infertility) (36). Environmental 
burdens having ED effects on the neuroendocrine functions may affect the individual, their 
life functions, quality of life and characters of their progeny in subsequent generations (14). 
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2. Objectives  
The problem area of endocrine disruption alluded to in the introduction suggests that today's 
medical science, including the challenges of endocrinology, has to face numerous 
environmental health risks. Disruption of the endocrine system, which actually affects the unity 
of the psycho-neuro-endocrine-immune system, may play a role in the development of many 
diseases. Thus, studying the changing environmental conditions in the living spaces provided 
by society and exploring the associations between exposures and consequent health problems 
can help us to reveal the pathomechanisms of certain systemic diseases. The most significant 
results of our data may be, however, that they should provide an aid in the formation of 
preventive measures. 
2.1. 
Endocrinological diseases connected to disturbances in cell transformation, particularly those 
leading to functional lesions in the thyroid (37) and pituitary (38), have become especially 
common. Thus, in the case of cell proliferative diseases of the thyroid (39) and the pituitary 
(40), it is a major health and therapeutic question whether the benign and/or malignant 
hypophysis and/or thyroid diseases should be investigated in connection with their pathogenic 
factors. 
a, - In this work, one of the basic questions was whether EDC could cause a disease in the 
thyroid via disordered transformation processes. To find an answer, identification of the 
disease, its diagnostic classification and exploration of case histories became necessary; 
b, - Whether ED effects could induce hypophysis cell transformation disturbances by generating 
endocrine regulatory disorders.  
2.2. 
The release of hormones into the blood flow through exocytosis provides active  
communication in the neuroendocrine regulation which is a prerequisite for maintaining a 
healthy homeostasis; the disruption of this process is a major pathogenetic factor (41). 
The questions arise whether hormone secretions do change due to ED effects in the neuro- and 
adenohypophysis; whether EDC cause adenohypophysis cell transformation; furthermore when 
reasonable ED effects can be detected, in which neuroendocrine diseases they may play a role; 
and finally whether the exploration of such pathomechanic factors have any significance from 
the viewpoint of environmental health. 
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a, - For this purpose, the clarification of the role of uron and halogenated hydrocarbon 
compounds used in agriculture has been the focus of our investigations in terms of EDC effects. 
These compounds exert continuous environmental exposure, not only via industrial and 
agricultural activities, but also through burdening the nutritional chain, and thus making them 
important from an environmental hygienic point of view.  
 b, - In the investigation of EMF effects on the cell membrane, the ED role was studied through 
the changes observed in membrane receptors. It was uncertain whether EMF could modify the 
functions of major monoamine receptors in the neuroendocrine regulation. Studying it through 
the disruption in the hormone secretion regulatory circuit (attractor) coupled with a given 
receptor function, obviously required a new research model.  
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3. Methods  
A. Human studies 
Characteristics of the patients  
Gender distribution: 78% (266 persons) of the 341 thyroid carcinoma patients are female, 22% 
(75 persons) are male. The incidence of the disease is 3.5 times higher among women. 
Age distribution: the average age of women is 58 years, the youngest being 20 years old, the 
oldest 87. The average age of men is 56 years, the youngest is 26, the oldest is 89 years old. 
Histological distribution: occurrence of histological types of thyroid carcinomas: 188 papillary 
(55%), 58 follicular (17%), 35 papillo-follicular (10%), 27 medullary (8%), 18 unknown (5%), 
9 Hürthle cell (3 %) and 6 anaplastic (2%). In women and men, the average age in papillary 
carcinoma patients is equally 56 years; 62 and 69 years for follicular carcinoma, 54 and 52 
years for medullary, 74 and 64 for anaplastic tumors.  
The risk of recurrence for differentiated thyroid carcinoma was classified by European Thyroid 
Association (ETA) and American Thyroid Association (ATA) methods (Table 1). 
 
 1 2 3 
ETA 
2006 
guidelines 
very low 
the tumor is unifocal T1 
(≤1 cm) N0M0 and there 
is no extension beyond 
the thyroid capsule 
low 
the tumor is T1 (>1 cm) 
N0M0, or T2N0M0, or 
multifocal T1N0M0 
high 
the tumor is any T3; any 
T4; any T with N1 or M1 
ATA 
2009 
guidelines 
low risk 
no local or distant 
metastases; no tumor 
invasion of local regional 
tissues; no aggressive 
histology or vascular 
invasion 
intermediate risk 
microscopic invasion of the 
tumor into the perithyroidal 
tissue; cervical lymph node 
metastases are present;  
high risk 
macroscopic tumor 
invasion; incomplete 
tumor resection; distant 
metastasis; 
thyroglobulinemia 
Table 1 Risk classification systems for differentiated thyroid carcinoma  
In the anamneses the effects of environmental (exposure to ED compounds) medic status were 
not examined by these classifications of thyroid differentiated carcinoma. In the endocrine 
regulation network, the linkage of TSH, anti-thyroglobulin antibody (anti-TG) and/or anti-thyroid 
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peroxidase antibody (anti-TPO) factors were not studied. In the present work, the diagnostic 
protocol was supplemented with environmental health issues in which we studied occupation, 
workplace, place of residence, number of electric devices inside and outside the home, plastic 
items and exposure to chemicals. We investigated (n=35) patients from the aspect of the 
relationship between the laboratory results (TSH, anti-TPO, anti-TG) and environmental health 
factors. Statistical analyses were carried out in SPSS (SPSS, Inc., Chicago, IL, USA, version 
22.0) and in Statistical software (Statistica 9.0, Statsoft, Tulsa, OK).  
 
Determination of hormone and antibodies 
Whereas the usual microsomal antibody tests employ unpurified microsomes as antigen 
preparation, the anti-TPO tests use a purified peroxidase. The two procedures are of comparable 
output in terms of clinical sensitivity, but better lot-to-lot consistency and higher clinical 
specificity can be expected from anti-TPO tests due to the superior quality of the antigen used. 
Recombinant antigen and polyclonal anti-TPO antibodies are used in the Elecsys Anti-TPO 
assay. Measuring range is 5.00-600 IU/mL (defined by the lowest detection limit and the 
maximum of the master curve). Values below the lowest detection limit are reported as <5.00 
IU/mL. Values above the measuring range are reported as >600 IU/mL. 
The anti-TG determination is used as an aid in the detection of autoimmune thyroid diseases. 
The Elecsys Anti-TG assay uses human antigen and monoclonal human anti-TG antibodies. 
Measuring range is 10.0-4000 IU/mL (defined by the lowest detection limit and the maximum 
of the master curve). Values below the lowest detection limit are reported as <10.0 IU/mL. 
Values above the measuring range are reported as >4000 IU/mL. 
The Elecsys TSH assay employs monoclonal antibodies specifically directed against human 
TSH. The antibodies labeled with ruthenium complex consist of a chimeric structure from 
human and mouse-specific components. As a result, interfering effects due to HAMA (human 
anti-mouse antibodies) are largely eliminated. Measuring range is 0.005-100 µIU/mL (defined 
by the lowest detection limit and the maximum of the master curve). The functional sensitivity 
is 0.014 µIU/mL. Values below the lowest detection limit are reported as <0.005 µIU/mL. 
Values above the measuring range are reported as >100 µIU/mL (or up to 1000 µIU/mL for 10-
fold diluted samples). 
TSH, anti-TPO and anti-TG were measured from serum using electrochemiluminescence 
immunoassay (ECLIA) on Modular E170 analyzer (Roche, Mannheim, Germany). 
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B. In vivo and in vitro experimental methods 
I. Experimental models 
1. Adenohypophysis (AdH) and prolactinomas adenohypophysis (PRLOMA) 
experiments 
Female Wistar rats (Charles River, Isaszeg, Hungary, medically certified) from different litters 
(weighing 120-250 g, aged 4-6 weeks at the beginning of the research) were used for 
hypophysis cell culture model systems. The animal care and research protocols were in full 
accordance with the guidelines of University of Szeged, Hungary. During the research period, 
rats were kept at a controlled relative air humidity of 55-65% and 22±2○C ambient temperature. 
Experimental animals lived on an automated diurnal cycle (12 h dark and 12 h light) in groups 
of 10 animals for 6 months. Standard pellet food and tap water were available ad libitum.  
2. AdH cell cultures  
After pentobarbital anaesthesia (4.5 mg/bodyweight kilogram (bw. kg), Nembutal, Abbott, 
USA) the normal animals were decapitated. Tissues were separated under a preparative 
microscope. Primary, monolayer cell cultures were prepared by enzymatic and mechanical 
dissociation. The tissues were digested enzymatically (trypsin: 0.2 % /Sigma, Germany/ for 30 
min; collagenase /Sigma, Germany/: 30 μg/ml for 40 min; dispase /Sigma, Germany/: 50 μg/ml 
for 40 min in phosphate-buffered saline /PBS-A/; temperature: 37°C). Mechanical dispersion 
was achieved with nylon blutex sieves (∅: 83 and 48 μm). Cultures were controlled for both 
viability (>95%; trypan blue exclusion) and function and the cell density was determined to be 
2x105/cm3. The dissociated cells were placed onto 24-well plastic plates (5% collagen coated 
/Nunc., Germany/; Dulbecco's Modified Essential Medium /DMEM/ + 20% Fetal Calf Serum 
/FCS/ + antibiotics /Penicillin+Streptomycin: 1.0 IU/ml/). The cells were cultured at 37 °C in a 
CO2 incubator that provided a humidified environment of 95% air and 5% CO2. The medium 
was changed every 3 days. Primary cell cultures were standardized by immunohistochemical 
methods, marking for prolactin (PRL) and adrenocorticotropic hormone (ACTH) release.  
3. Induction of prolactinoma and PRLOMA cell culture 
Female Wistar rats (n=20) were treated subcutaneously with estrone-acetate (CAS registry 
number: 901-93-9, Sigma, Germany; 150 μg/bw. kg/week) for 6 months to induce 
adenohypophyseal prolactinomas. After pentobarbital anaesthesia (4.5 mg/bw. kg, Nembutal, 
Abbott, USA) the treated (prolactinomas adenohypophysis: PRLOMA) animals were 
decapitated. Tissues were separated under a preparative microscope. Primary, monolayer cell 
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cultures were prepared by enzymatic and mechanical dissociation. The tissues were digested 
enzymatically (trypsin: 0.2 % /Sigma, Germany/ for 30 min; collagenase /Sigma, Germany/: 30 
μg/ml for 40 min; dispase /Sigma, Germany/: 50 μg/ml for 40 min in phosphate-buffered saline 
/PBS-A/; temperature: 37°C). Mechanical dispersion was achieved with nylon blutex sieves (∅: 
83 and 48 μm). Cultures were controlled for both viability (>95%; trypan blue exclusion) and 
function and the cell density was determined to be 2x105/cm3. The dissociated cells were placed 
onto 24-well plastic plates (5% collagen coated /Nunc., Germany/; Dulbecco's Modified 
Essential Medium /DMEM/ + 20% Fetal Calf Serum /FCS/ + antibiotics 
/Penicillin+Streptomycin: 1.0 IU/ml/). The cells were cultured at 37 °C in a CO2 incubator that 
provided a humidified environment of 95% air and 5% CO2. The medium was changed every 
3 days. Primary cell cultures were standardized by immunohistochemical methods, marking for 
PRL and ACTH release.   
4. Neurohypophysis (NH) cell culture model 
Male Wistar rats (Charles River, Isaszeg, Hungary, medically certified) from different litters 
(weighing 120-250 g, aged 4-6 weeks at the beginning of the research) were used for 
hypophysis cell culture model systems. The animal care and research protocols were in full 
accordance with the guidelines of the University of Szeged, Hungary. During the research 
period, rats were kept at a controlled relative air humidity of 55-65% and 22±2 °C ambient 
temperature. Experimental animals lived on an automated diurnal cycle (12 h darkness and 12 
h light system) in groups of 10 animals. Standard pellet food and tap water were available ad 
libitum. After pentobarbital anaesthesia (4.5 mg/bw. kg, Nembutal, Abbott, USA) the animals 
were decapitated. NH tissues were separated under a preparative microscope. The NH tissue 
was digested enzymatically with 0.2% trypsin (Sigma, Germany) in phosphate-buffered saline 
for 60 min, and with 0.05% collagenase (Sigma, Germany) for an additional 60 min at 37 °C. 
The enzymatic hydrolysis was stopped by the addition of 100 µg/ml trypsin inhibitor (Sigma, 
Germany). Mechanical disintegration of the tissue was performed on nylon blutex sieves (pore 
sizes 100, 80 and 48 µm in series). Cultures were controlled for both viability (>95%; trypan 
blue exclusion) and function and the cell density was determined to be 2x105 cells/mL. The 
dispersed cells were placed onto 24-well plastic plates (Costar, USA) coated with 5% rat tail 
collagen (Sigma, Germany). The starting cell density was 2x105 cells/mL of medium 
(Dulbecco’s Modified Eagle’s Medium; Sigma, Germany) supplemented with 20% foetal calf 
serum (Gibco, USA), 0.1 µg/L PenStrep (Sigma, Germany). The cell cultures were maintained 
at 37 °C in a humidified atmosphere of 5% CO2 in air. The culture medium was changed every 
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3 days. The 14 day old neurohypophysis primary cell cultures were standardized by 
immunohistochemical methods (by relative incidence/unit plate-area of immunoreactive (IR) 
content oxytocin (OT) or 8-arginine vasopressin (AVP) cells), and the OT and AVP time-
release kinetic activity was determined. After these procedures the basal OT and AVP levels 
were measured by radioimmunoassay (RIA) methods in the neurohypophysis cell cultures. 
II. ED treatments 
5. Investigation model for effects of change extracellular ionic milieu by AdH and 
PRLOMA cells  
After functional standardization, the basal ACTH and PRL levels were determined in both 
normal primary adenohypophysis cell cultures and primary monolayer PRLOMA cell cultures 
(Tyrode’s medium /Sigma, Germany/). In the medium, only the [Ca2+] was modified; all other 
essential anions and cations were under homeostatic (e.g. isoionic) conditions. The hormone 
release of primary cell cultures was detected under hypocalcaemic conditions of varying 
degrees ([Ca2+]: 0; 0.5; 1.0; 1.5 mM; n=12 in each group). Samples were taken at 10, 20, 30, 
60 and 90 minutes after treatment to measure hormone kinetics. The PRL and the ACTH 
contents were detected in the supernatant media. ACTH and PRL were determined by 
luminescence immunoassay (LIA) and RIA methods (3.B.II.6).  Protein content of the hormone 
releasing cells was assayed by a modified Lowry-method (42), and Pierce BCA Protein Assay 
Kit was used (Thermo Fisher Scientific Inc., Rockford, USA).  
Statistical analysis 
Repeated measurements of ACTH and PRL hormone release in different treatment groups on 
cell cultures (time points at 10, 20, 30, 60 and 90 minutes; n=12 in each group) were compared 
using marginal models (also known as population average models). Restricted maximum 
likelihood estimation and Kenward-Roger method for adjusting the degrees of freedom were 
applied. In the case of ACTH, unstructured covariance matrix, for PRL data, the heterogeneous 
first order autoregressive covariance matrix resulted in the best fit among different structures 
(variance components, compound symmetry, first order autoregressive, toeplitz, unstructured 
and their heterogeneous versions), based on Akaike's information criterion (AIC) statistic. 
Pairwise comparisons were estimated by least squares means using Sidak p-value adjustment. 
Model residuals were displayed on quantile-quantile plots to check normality assumptions. In 
the case of extreme values, winsorization technique was applied by shifting the strongly 
outlying data toward the center to protect parameter estimation against the emergence of 
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unexpectedly large errors. Statistical analyses were performed in SAS (Version 9.3 SAS 
Institute Inc., Cary, NC, USA), where p-values of <0.05 were considered to indicate statistical 
significance (43). 
6. Investigation of EDC Effects on AdH and PRLOMA Cell Culture Models 
EDC treatment groups were set up with the primary monolayer AdH and PRLOMA. Functional 
standardization was performed to verify specific and non-specific ACTH hormone release 
functions. In the constant ionic concentration medium, non-specific hormone release was 
induced by +30 mM [K+] for 20 min /control AdH sample: 1528 pg ACTH/mg protein (AdH); 
+30 mM [K+] AdH sample: 3871 ACTH/mg protein (AdH); PRLOMA sample control: 2198 
pg ACTH/mg protein (PRLOMA); +30 mM [K+] PRLOMA sample: 5923 pg ACTH/mg 
protein (PRLOMA)/. Specific functional ACTH release control was regulated by 1μg/ml 
corticosterone (B) and 10-6 M AVP treatments. 
Experimental protocol  
For our experiments, the time and dose kinetic assays determining the effects of uron and 
chlorobenzene (ClB) derivatives were performed on standardized AdH and PRLOMA in vitro 
cultures. AdH and PRLOMA cell cultures were first treated for 60 minutes with 1,4-
dichlorobenzene (dClB: [0.1 ng/ml]), chlorobenzene mix (mClB: [0.1 ng/ml]: 
hexachlorobenzene + 1,2,4-trichlorobenzene=1:1) and uron derivatives (phenuron [PU]: 
10-6 M; monuron [MU]: 10-6 M; diuron [DU]: 10-6 M). At the end of the EDC treatment periods 
samples for hormone determination were obtained from the supernatant media of the cell 
cultures. Basal ACTH and PRL hormones release were determined. When studying the ACTH 
mediated role of EDC agents in the hypophysis/adrenal cortex regulation, the EDC agents were 
co-administered with AVP [10-6 M] and after the 60 minute treatment period, the samples were 
taken from the supernatant media of both AdH and PRLOMA for the determination of released 
ACTH. In the regulation cycle of AVP/corticosterone (B) feedback studies in Figure 1, ED 
were added together with B. AVP was administered after a 20 minute pre-treatment with EDC 
+ B, and at the end of the treatment period, the supernatant media was sampled.  
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Figure 1 Functional assay for ACTH release in normal rat adenohypophysis cultures, in 
vitro 
(n = 8-12 in each group); mean level ± standard error of the mean (SEM) (pg ACTH / mg protein): AVP 
significantly increases (p<0.001), whereas corticosterone alone does not alter ACTH release when compared to 
control; preincubation with + B inhibited AVP activation. (basal: control; AVP: 8-arginine vasopressin; B: 
corticosterone) 
 
Statistical analysis – in AdH/PRLOMA EDC effect protocol 
Measurements (n=8-12 per group on 24 lots: pooled samples on AdH cell cultures) of ACTH 
and PRL hormone release by disease (PRLOMA, AdH) in different EDC groups (Control, 
dClB, mClB, PU, MU, DU) by regulation (base, +AVP, +B, +B+AVP, +AVP+B) were 
compared using mixed models on rats (44). The regulation cycle was verified in a mixed model 
for the comparison of the control groups of EDC for ACTH in the 5 regulation phases, using 
disease and regulation as fixed effects and random intercept for the lots. For ACTH data a mixed 
model was applied with disease, EDC and regulation (only base, +AVP, and +B+AVP) as fixed 
factors and random intercept for the lots. For PRL measurements a mixed model was applied 
with disease and EDC as fixed factors and random intercept for the lots for basal regulation 
data. In the analysis models the reference group was the normal (healthy AdH) control (no EDC 
treatment) base (no regulation) group. Restricted maximum likelihood estimation and 
Kenward-Roger method for adjusting the degrees of freedom were applied in all models with 
unstructured covariance matrix. Pairwise comparisons were estimated by least squares means 
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using Sidak p-value adjustment. Model residuals were displayed on quantile-quantile plots to 
check normality assumptions. Statistical analyses were performed in SAS (Version 9.3 SAS 
Institute Inc., Cary, NC, USA), where p-values of <0.05 were considered to indicate statistical 
significance (43). 
Determination of hormone content and adenosine triphosphate (ATP)ase activity 
The rat PRL RIA KIT (Institute of Isotopes Ltd., Budapest, Hungary) was used to determine 
the supernatant PRL content; all components were stored at 2-8 ºC, where they were stable. 
Non-specific binding, defined as the proportion of tracer bound in the absence of antibody, was 
determined to be <5%. The sensitivity of the RIA procedure was 0.07 ng/tube. The intra-assay 
precision obtained was 0.92 ± 0.03 ng. PRL data are given in ng PRL / mg protein. The Mg2+-
dependent ATPase activity was measured by the modified method of Martin and Dotty (62). 
From the supernatant media, 500 µL samples were removed by Gilson pipette at appropriate 
times and stored at -80°C until LIA was performed. The ACTH levels of supernatant media 
were measured by LIA with an Immulite 2000 apparatus (Siemens Healthcare Diagnostic, 
Deerfield, IL) and Diagnostic Product Corporation kit (L2KAC-02; Euro/DPC Ltd, Glyn 
Rhonwy, UK). ACTH data are given in pg ACTH / mg protein. 
7. Treatment of Wistar rats with ED agents in vivo  
In vivo treatment of Wistar male rats with mClB (dose of mClB: 0.1, 1.0 and 10 µg/bw. kg; 
n=10/group; duration of exposure: 0 day control, treatment: 30, 60 and 90 days) was made using 
a gastric tube, in 1ml of 0.015% ethanol in distilled water. In the control system, no treatment 
was used for absolute controls; in the stress controls, empty stomach tubes were used; in the 
case of negative controls, 1 ml of final drinking water was injected; in the positive controls, the 
solvent for ClB was injected in the same volume. In the experimental protocol, ACTH was 
determined from the serum samples (Immulite 2000 ACTH test kit, Siemens Healthcare 
Diagnostic, Deerfield, IL, USA). According to 3.B.I.2. cell cultures were made and the ACTH 
release was followed. There was no significant difference between the control group results 
when analyzing ACTH measured values, thus our results only show absolute control data. To 
the statistical analyse IBM SPSS Statistics, Version 21 programbag was used.  
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8. Investigation of ED Effects on NH Cultures 
NH cell culture treatment protocol (Figure 2) 
 
Figure 2 The in vitro treatment protocol 
PU: phenuron, DU: diuron, MU: monuron, E: epinephrine, NE: norepinephrine, 5-HT: serotonin, HA: histamine, 
DA: dopamine, OT: oxytocin, AVP: 8-arginine vasopressin 
 
The control samples were untreated and served as self-controls, which showed the basal release 
(60 min) of OT and AVP in NH. The effects of PU, MU and DU added to the NH for 60 minutes 
at a concentration of 10-6 M were examined one by one (45) /PU (CAS registry number: 101-
42-8), DU (CAS registry number: 330-54-1) and MU (CAS registry number: 150-68-5) (Sigma, 
Germany)/. In our earlier studies dose dependent kinetics of phenylurea agents were 
determined, and the present experimental doses were selected in accordance with our previous 
results, because the saturation of receptor binding sites depends on the affinity and number of 
receptor binding molecules. Monoamine activated G-protein receptors in NH were treated with 
10-6 M (epinephrine: E, norepinephrine: NE, serotonin: 5-HT, histamine: HA, dopamine: DA) 
(Figure 3) for 30 min (46, 47, 48, 49, 50) and the same concentration (10-6 M) of phenylurea 
agents. 
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Figure 3 The effect of monamines on OT (3A) and AVP (3B) release in neurohypophysis 
cell cultures 
Pairwise comparisons verified the regulation cycle: all monoamine 10-6 M groups increased significantly 
(***p<0.0001) compared to the basal regulation in control OT (n=12) and AVP (n=10). All data presented as 
mean±SEM 
 
The combined treatment groups of the NH were treated firstly with monoaminergic compounds 
(for 30 min), then phenylurea compounds (for 60 min) (1. E+PU, NE+PU, 5-HT+PU, HA+PU, 
DA+PU; 2. E+MU, NE+MU, 5-HT+MU, HA+MU, DA+MU; 3. E+DU, NE+DU, 5-HT+DU, 
HA+DU, DA+DU). 
The OT and the AVP contents were detected in the supernatant media. From the supernatant 
media, 500 µl samples were removed by Gilson pipette at appropriate times and stored at -80 °C 
until peptide RIA was performed to measure OT and AVP (51, 52).  
A modified Lowry Method (42) and Pierce BCA Protein Assay Kit (Thermo Fisher Scientific 
Inc., Rockford, USA) were used for the determination of total protein content. 
 
Statistical analysis 
Pooled samples of neurohypophysis cell cultures (12 lots) were measured for OT and AVP 
hormone release in different EDC groups (control, PU, MU, DU) by monoamine regulation 
(basal, E, NE, 5-HT, HA, DA) in rats (n=10 or 12 per group). Data were analyzed using mixed 
models (44, 53).  The monoamine regulation cycle was verified in mixed models for the 
comparison of 6 monoamine levels in the control groups for OT and for AVP. In the random 
intercept model monoamine was used as the fixed factor and the lots as the intercept. For the 
two investigated hormone data (OT, AVP) mixed models were applied with EDC and 
monoamine as fixed effects and random intercept for the lots. In the analysis models the 
reference group was the control (no EDC treatment) basal (no monoamine) group.  
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Restricted maximum likelihood estimation and Kenward-Roger method for adjusting the 
degrees of freedom were applied in all models with unstructured covariance matrix. Pairwise 
comparisons were estimated by least squares means using Sidak p-value adjustment. Model 
residuals were checked for normality assumptions. Statistical analyses were performed in SAS 
(Version 9.3 SAS Institute Inc., Cary, NC, USA), where p-values of <0.05 were considered to 
indicate statistical significance (43). 
 
9. ED impact assessment of in vivo extremely low frequency and dose electromagnetic 
field (ELF-EMF)   
Female adult turkeys (from state farm, 5000-5200 g) with veterinary certificate were used as 
the model system. The animal care and research protocols were in full accordance with the 
guidelines of the University of Szeged, Hungary. 
Four animals served as control (absolute control (AC) – untreated; positive control (+C) – 
equipment was in standby mode; negative control (-C) – the machine was switched off; sham 
control (SC) – the bird went through the protocol without receiving any EMF exposure). Forty 
animals were treated with intermittent ELF-EMF. The animals were individually numbered.  
Experimental Conditions 
The turkeys were kept together during the experimental process except the treatment time. For 
the treatment, they were put separately in metal-free cages. At the beginning of the experiment, 
the animals were conditioned for 1 week (adaptation period) to eliminate the stress effects 
(possibly caused by the new surroundings, animal caregiver, food, etc.).  
ELF-EMF Treatment 
The treatment was performed using a special unit designed for the generation of pulsed ELF- 
EMF (8 ms energy exposure – 2 ms energy free pause; these were controlled by an 
electromagnetic equipment: ME3951A, Gigahertz Solutions, Germany). During treatment, the 
cages were covered by a 200 cm × 80 cm “magnetic blanket” that was operated by the 
Hungarian electric regulation (U=220 V, ν=50 Hz). The turkeys were exposed to ν=50 Hz, 
B=10 μT intermittent ELF-EMF treatment for 20 minutes every 8 hours for the 3 weeks of the 
experimental period.   
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In Vivo experiments (Figure 4a) 
Monitoring of Behavior  
The animals were regularly observed for physical activity (relaxation, play, behavior, 
competition, aggression) and food and water consumption (54). 
Blood Samples 
Heparinized blood samples were taken from the subclavian vein at the same time every week 
during the experiment. All measurements were performed from 4-6 technical parallels. Blood 
samples were separated by centrifugation for 5 min at 2000 rpm. After removing the blood 
plasma, the red blood cells (RBC) were washed 3 times with 0.9% saline solution. At the end 
of the procedure, the erythrocytes were suspended in Ringer solution buffered by 10 mM 
TRIS/HCl; pH 7.4 and hematocrit value was 20%.  
Toxicological Monitoring from Turkey Blood-serum Enzyme Measurements 
During the experiment, the following biochemical enzyme parameters were measured from the 
blood: serum glutamic oxaloacetic transaminase (SGOT) (55), serum glutamic pyruvic 
transaminase (SGPT) (56), alkaline phosphatase (AP) and gamma-glutamyl transpeptidase 
(γGT) with Dialab methods (Dialab Production, Austria). Lactate dehydrogenase (LDH) 
activity was also measured (55).  
 
Figure 4 Structure of the ELF-EMF experimental model 
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In Vitro Experiments (Figure 4b) 
Incubation Protocol 
In the first in vitro experimental step, the baseline intracellular 3’-5’cyclic adenosine 
monophosphate (cAMP) was determined from all blood samples. For the study of the activation 
of β-adrenergic receptor, an agonist ([NE]=10-6 M; t=30 min) as well as an antagonist 
(propranolol (P): [P]=10-6 M; t=30 min) were used both separately and combined. Combination 
means that the agonist was added at a concentration of 10-6 M to the erythrocytes after a 30 min 
pre-incubation with the antagonist at a concentration of 10-6 M. In all procedures, the 
intracellular cAMP level was measured after incubation. (Figure 5) 
 
Figure 5 Verification of in vitro experimental model for NE-activated beta-adrenoceptor 
function at adaptation (week 1, no ELF-EMF exposure) 
Mean (cAMP levels) ±SEM at adaptation (week: wk 1). Mean and SEM are calculated on n = 40 animals 
(treated group from wk 2). Notation: ELF, extremely low frequency and dose; EMF, electromagnetic field; 
cAMP: 3’-5’cyclic adenosine monophosphate; Base: baseline; NE: norepinephrine; P: propanolol; nmol/mL, 
nmol cAMP/mL RBC SUSP: RBC: red blood cells; SUSP: suspension. *** indicates difference between pairs of 
NE and all other groups with Type I error α=0.001. 
Hemoglobin Determination: the hemoglobin was transformed into cyanohemoglobin, which 
was detected photometrically (λ=540 nm) (57).  
Determination of cAMP Level: in vitro samples were taken from RBC suspension (SUSP) of 
turkeys. These were denatured at 100 °C for 3 minutes, and kept at -20 °C until further use. 
Before cAMP determination, the samples were defrosted and precipitated (at 0 °C, 1600 rpm, 
t=1 min). The cAMP content of samples was quantitated by competitive binding assay 
(Amersham cAMP Biotrak EIA system, GE Healthcare, UK).  
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Statistical Analysis 
Means were calculated from technical replicates for each subject (experimental unit: turkey), 
and used for analyses of cAMP levels (as a marker of β-adrenoceptor function). Descriptive 
statistics (mean, standard deviation (SD), n, minimum, median, maximum) were calculated to 
identify distribution of cAMP levels by treatment groups and time points. To verify the β-
adrenoceptor function in the in vitro experimental model during the adaptation period (week: 
wk 1), cAMP levels were compared between groups of base, NE, P and P+NE, based on linear 
mixed model using random intercept for the subjects (43, 53). Mean cAMP levels of n=40 
animals (selected for ELF-EMF treatment from wk 2) and standard errors (SE)s are presented.  
To compare NE-activated β-adrenoceptor function of control animals (n=4) to the average 
cAMP levels of turkeys (n=40 and n=44) at the adaptation period (wk 1), one-sample t-tests 
were applied. 95% confidence intervallum (CI)s are presented with means and P-values (P). 
Effects of ELF-EMF treatment on NE-activated β-adrenoceptor function were analyzed using 
a linear mixed model where cAMP levels of the treatment period (wk 2-4) as repeated measures 
of treated animals (n=40) were compared to the cAMP levels at the adaptation period (wk 1). 
To estimate means in ELF-EMF treated and untreated groups over time in the whole 
experimental period (wk 1-9) considering between-subject differences and within-subject 
correlation, marginal model was applied using unstructured covariance structure (53). 
Differences of least squares means are calculated according to Sidak’s adjustment. To 
characterize the reversible nature of NE-activated β-adrenoceptor function after ELF-EMF 
treatment by the rate of change in time, piecewise linear mixed model was used, which could 
describe the linear trajectories of cAMP levels in the treatment and in the regeneration periods 
(53). An intraclass correlation coefficient was calculated to describe variation. In marginal and 
mixed models, the restricted maximum likelihood estimation method was used with 
unstructured covariance structure. Model residuals were checked for normality. All statistical 
analyses were performed using SAS (Version 9.3 SAS Institute Inc., Cary, NC, USA), with 
Type I error α=0.05 (43).   
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4. Results  
In connection with 2.1.a objective, screening of patients, their diagnostic and therapeutic 
approach were made with regard to the possible endocrine disruptor effects.   
For better understanding the thyroid diseases, ED effects are to be revealed during the 
endocrinological examination of the patients, as they may be crucial in the regulation of 
metabolism in thyroid cell transformation. We examined 341 thyroid cancer patients whose 
therapeutic results are presented below.  
These 341 patients were treated according to the therapeutic protocol as follows: 244 cases 
(72%) with total thyroidectomy, 44 patients (13%) with subtotal thyroidectomy and the 
remaining 53 patients (15%) had other types of surgery (lobectomy, debulking) or no surgery 
was performed. After surgical intervention, I-131 radioiodine therapy was applied in 199 (59%) 
patients, whereas 142 patients (41%) were not given I-131 treatment or information is missing 
in this respect. Among the radioiodine-treated patients, 66 (34%) had one, 59 (30%) two, and 
30 (15%) received three doses of therapeutic radioiodine. In two cases extremely multiplied 
(ten or eleven) radioiodine treatments were needed. Average dose per treatment: ablative: 1850-
3700 megabecquerel (MBq), therapeutic: 3700-7600 MBq. Eighteen patients (5%) were treated 
with external radiation. In the background of the increasing occurrence of thyroid tumors, we 
have started to clarify the role of ED effects by extended diagnostic procedures (biochemical 
markers and detailed case history data). 
Table 2 shows that, in addition to the TSH values at the establishment of diagnosis, the 
elevations of anti-TG and/or anti-TPO levels demonstrated a relationship between malignant 
thyroid tumor and autoimmune thyroid disorder. Into the present ED effect study, the tabulated 
individuals were enrolled with markedly increased antibody levels (Table 3). 
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 data 
code 
age ATA ETA TSH 
(mIU/l) 
anti-TG 
(IU/ml) 
anti-TPO 
(IU/ml) 
control     0,27-
4,29 
<115 <34 
1 AE 29 1 2 4.67 3298 >600 
2 BA 18 2 3 1.59 1125 242 
3 BB 18 2 3 2.32 24.51 10.35 
4 CSB 44 1 2 1.8 - 12.44 
5 CP 66 2 3 2.44 855 - 
6 DA 60 1 2 3.14 20.29 - 
7 DI 64 1 2 2.46 34.1 - 
8 DM 36 2 3 2.94 56.3 - 
9 FI 38 1 2 3.32  23.59 
10 HE 52 1 2 5.15 45.46 - 
11 HL 76 1 2 1.30 21.55 8.24 
12 HB 29 2 3 2.61 15.53 7.31 
13 JA 23 1 2 0.85 <10.10 - 
14 KS 43 2 3 3.28 704 - 
15 KG 54 2 3 0.96 238 - 
16 KAN 18 1 2 1.35 304.40 - 
17 KI 59 1 2 0.72 28,72 - 
18 MZS 50 1 2 1.38 46,16 - 
19 MA 42 2 3 1,81 367.80 - 
20 NN 32 1 2 1.11 - 17.87 
21 NBA 22 1 2 0.97 18 - 
22 RV 55 2 3 1.36 458.3 78.39 
23 SA 35 2 3 11.13 - 282 
24 SR 39 2 3 2.24 10.20 - 
25 SZJ 61 2 3 0.45 - 8.65 
26 SZI 77 1 2 0,68 10.47 - 
27 SZT 27 1 2 1.52 22.48 - 
28 TKM 40 1 2 1.44 38.4 - 
29 TFP 48 1 2 1.05 19.71 - 
30 TI 54 1 2 1.42 12.94 - 
31 TT 21 1 2 0.80 - 10.76 
32 TGYL 84 1 2 2.44 13.44 - 
33 VSG 38 2 3 6.24 - >600 
34 VM 59 1 2 3.2 13.72 - 
35 ZK 64 2 3 1.46 34.81 - 
 
Table 2 Parameters and classification (ATA, ETA) of thyroid cancer patients (58, 59) 
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 data 
code 
age TSH 
(mIU/l) 
anti-
TG 
(IU/ml) 
anti-
TPO 
(IU/ml) 
TSH/anti-
TG x 10-6 
TSH/anti-
TPO x 10-6 
environmental 
factors 
control    0.27-
4.20 
<115 <34 <4.29/115  <4.29/34  
median 0.0353475 0.057794  
1 AE 29 4.67 3298 >600 0.00141* < 0.007789* 9 
2 BA 18 1.59 1125 242 0.00141* 0.00657* 8 
5 CP 66 2.44 855 - 0.002853* - 8 
14 KS 43 3.28 704 - 0.004659* - 8 
15 KG 54 0.96 238 - 0.004033* - 9 
16 KAN 18 1.35 304.40 - 0.004434* - 6 
19 MA 42 1.81 367.80 - 0.004921* - 8 
22 RV 55 1.36 458.3 78.39 0.002967* 0.017349* 7 
23 SA 35 11.13 - 282 - 0.039468* 8 
33 VSG 38 6.24 - >600 - < 0.0104* 6 
TSH: thyroid-stimulating hormone; anti-TG: anti-thyroglobulin antibody; anti-TPO: anti-thyroid peroxidase 
antibody, 
*p<0.01 relation to the median 
 
Table 3 Increased autoimmune parameters (anti-TG, anti-TPO) in thyroid cancer (58) 
 
 
TSH data related to thyroid autoimmune parameters (TSH/anti-TPO, TSH/anti-TG) were 
always lower than the calculated median of the controls. These parameters were correlated with 
the presence of additional ED factors in the medical history.  
 
The AVP-induced ACTH release of normal AdH cells can be inhibited by corticosterone (B) 
pretreatment in vitro. The basic ACTH release was significantly increased in the presence of 
10-6M AVP (60 min), which was prevented by (20 min) pre-administration of 1 µg / ml B prior 
to AVP (Figure 1). We also investigated the ACTH-release stimulating effect of AVP on 
experimentally produced PRLOMA cells, where a significantly increased ACTH-response was 
found when compared to normal AdH; increased basal ACTH release and increased AVP 
activated ACTH release (Figure 6). 
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Figure 6 Functional assay for ACTH release in rat prolactinomas adenohypophysis cell 
cultures (PRLOMA), in vitro 
(n=11-12 in each group); mean level ±SEM (pg ACTH/mg protein): Compared with normal AdH cells (Figure 
1) ACTH release always shows a similarly significant (p<0.001) increase in PRLOMA cells. (basal: control; 
AVP: 8-arginine vasopressin; B: corticosterone) (45) 
 
Transformed cells induced by disturbance of the endocrine regulatory cycle, PRLOMA cells, 
whose cell cultures showed a significant increase in PRL secretion compared to AdH cell 
cultures (Table 4).  
 
 PRL release (ng PRL/mg protein) 
control 
normal AdH PRLOMA 
7.13±0.04 17.14±0.02 
Table 4 Basal PRL release from normal AdH and PRLOMA cell cultures, in vitro 
(mean level±SEM; n=12) (45) 
 
Changes in the behavior of the cells of healthy adenohypophysis versus transformed 
prolactinomas adenohypophysis have also been examined at low extracellular calcium ion 
concentrations [Ca2+]. Their membrane function was evaluated by exocytotic activity (ACTH, 
PRL). Figure 7 shows the ACTH release of both the normal AdH control systems and the treated 
groups. Our experiments revealed statistical differences between treated and untreated groups. 
In Figure 7 the ACTH content of the absolute control group in its supernatant media was 
compared with that of the groups treated with 0 and 0.5 mM [Ca2+]. During this experiment, 
the ACTH release of the treated groups decreased appreciably when compared to controls. It 
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was found that at 60 and 90 min of the experiment the hormone content in the supernatant 
medium was higher at the 0 mM groups than at the 0.5 mM groups. 
 
 
Figure 7 The effects of low Ca2+ milieu on ACTH release from AdH cell cultures 
Cell cultures (n=12) were treated as follows [Ca2+]: 0, 0.5, 1.0, 1.5 mM. After treatment samples from the 
supernatant media were taken at 10, 20, 30, 60, 90 minutes. *** indicates the significant differences between the 
hormone release from various treated groups versus the ACTH release from normal AdH as the control group. 
The level of significance was chosen as p<0.0001. (60) 
 
 
The basal PRL release from the control AdH systems and the treated primary cell cultures are 
represented in Figure 8. The hormone levels in the medium of cell cultures treated with 1.0 mM 
Ca2+ (Figure 8) were reduced significantly depending upon the duration of exposure, in contrast 
to the control groups. The hormone levels of the supernatant media in 1.5 mM Ca2+ treated 
groups decreased significantly. As shown in Figure 8, the PRL release was reduced significantly 
by the effects of 0 and 0.5 mM Ca2+ depending upon the duration of exposure. Figure 8 also 
shows that the levels of PRL were reduced significantly by the effects of 1.0 mM Ca2+ compared 
with the controls. PRL release at the cardinal points of the research protocol decreased 
significantly. 
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Figure 8 The effects of low Ca2+ milieu on the PRL release from adenohypophysis (AdH) 
monolayer cell cultures 
Cell cultures (n=12) were treated as follows [Ca2+]:0, 0.5, 1.0, 1.5 mM. After treatment, samples from the 
supernatant media were taken at 10, 20, 30, 60, 90 minutes. *** indicates the significant differences between the 
PRL release of various treated groups versus the PRL release of normal AdH as the control group. The level of 
significance was chosen as p<0.0001. (60) 
 
 
Figure 9 shows the ACTH release from the PRLOMA cell culture systems: non-treated control 
and low Ca2+ treated PRLOMA groups.  
As shown in Figure 9, at 10 min of the experiment the ACTH of PRLOMA cell cultures treated 
with 0 mM Ca2+ was enhanced compared with that of the control groups. In the supernatant 
media, the ACTH levels decreased significantly in both treated groups compared with the 
controls depending upon the duration of exposure. It was observed that the ACTH release of 
PRLOMA cell cultures treated with 0 mM Ca2+ increased significantly at 90 min of the 
experiment. 
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Figure 9 The effects of low Ca2+ milieu on the release of ACTH from PRLOMA cell 
cultures 
Cell cultures (n=12) were treated as follows [Ca2+]: 0, 0.5, 1.0, 1.5 mM. After treatment, samples from the 
supernatant media were taken at 10, 20, 30, 60, 90 minutes. *** indicates the significant differences between the 
ACTH release of various treated PRLOMA groups versus the ACTH release of PRLOMA control group. The 
level of significance was chosen as p<0.0001. xxx indicates that the control is not significantly different from the 
data of PRL release at 0mM [Ca2+]. (60) 
 
In Figure 10, it can be seen that the PRL release from PRLOMA cell cultures, under different 
hypocalcaemic conditions, decreased significantly depending upon the duration of exposure 
compared with the control group. Astonishingly, notable enhancement was detected in the PRL 
release from the groups treated with 1.5 mM Ca2+. At 90 min of the experiment, the PRL content 
of the media increased significantly as a consequence of 0 mM Ca2+ against the control. 
 
 
The ED effects of urons and chlorobenzenes used in agriculture were investigated on AdH and 
PRLOMA models by monitoring their hormone release (ACTH, PRL) influencing functions. 
Figure 10 The effects of low Ca2+ milieu on the PRL release from PRLOMA cell cultures 
Cell cultures (n=12) were treated as f llows [Ca2+]: 0, 0.5, 1.0, 1.5 mM. Aft  treatment s mples from the 
supernatant media were taken at 10, 20, 30, 60, 90 minutes. *** indicates the significant differences between 
the PRL release of various treated PRLOMA groups versus the PRL release of PRLOMA control group. The 
level of significance was chosen as p<0.0001. (60) 
29 
 
According to objective 2.2.a, Figure 11 shows the effect of various ED compounds (dClB, 
mClB, PU, MU, DU) on ACTH release from AdH cultures under the following circumstances: 
basal, AVP activated (+AVP) and the corticosterone-inhibited AVP activation (+B +AVP) in 
AdH cultures. It can be seen that ACTH release was not altered by ED agents compared to the 
control group. In the AVP activated samples, ACTH release showed a significant increase 
compared to the control group even in the presence of each EDC. Under regulatory effects (+B 
+AVP-feedback), large deviations could not be detected even in the presence of each EDC. 
 
 
Figure 11 EDC effects in the regulation of ACTH release from normal rat AdH cultures, 
in vitro 
mean (ACTH level) ± SEM; The mean and SEM are calculated from n=12. Abbreviations: corticosterone [B]: 1 
μg/ml; [AVP] (8-arginine vasopressin): 10-6 M, + B + AVP: in combination therapy B precedes AVP 
administration by 20 minutes; [dClB] (1,4-dichlorobenzene): 0.1 ng/ml; [mClB] (chlorobenzene mix): 0.1 
ng/ml]; [PU] (phenuron): 10-6 M; [MU] (monuron): 10-6 M; [DU] (diuron): 10-6 M; AdH: adenohypophysis; 
ACTH: adrenocorticotropic hormone. All EDC groups differ significantly from the control (p<0.001) for +AVP. 
(45) 
 
 
Figure 12 shows the effects of dClB, mClB, PU, MU, DU on ACTH release from PRLOMA 
cultures under the following circumstances: basal, AVP activation (+AVP) and corticosterone 
inhibited AVP activation (+B+AVP). It can be seen that ED agents modulate ACTH release 
compared to the control basal group. AVP activated ACTH release from PRLOMA cultures 
shows a significant increase for each ED compound used. EDC effects were detected in the 
regulation model (+B+AVP-feedback) as well. 
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Figure 12 EDC effects on the regulation of ACTH release from rat PRLOMA cultures, 
in vitro 
mean (ACTH level) ± SEM; The mean and SEM are calculated from n=12. Abbreviations: [corticosterone] [B]: 
1 μg/ml]; [AVP] (8-arginine vasopressin) 10-6 M, +B+AVP: in combination therapy B precedes AVP by 20 
minutes; [dClB] (1,4-dichlorobenzene): 0.1 ng/ml; [mClB] (chlorobenzene mix): 0.1 ng/ml; [PU] (phenuron): 
10-6 M; [MU] (monuron): 10-6 M; [DU] (diuron): 10-6 M; PRLOMA: prolactinomas adenohypophysis ; ACTH: 
adrenocorticotropic hormone. All EDC groups differ significantly from the control (p<0.001) for basal, +AVP 
and +B +AVP. (45) 
 
 
 
Figure 13 shows the PRL release from AdH cultures in the presence of the ED compounds 
tested. It can be seen that the ED compounds did not cause relevant differences in PRL release. 
 
 
Figure 13 Effects of EDC on PRL release from normal rat AdH cultures, in vitro 
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mean (PRL level) ± SEM; The mean and SEM are calculated from n=12. Abbreviations: [dClB] (1,4-
dichlorobenzene): 0.1 ng/ml; [mClB] (chlorobenzene mix): 0.1 ng/ml; [PU] (phenuron): 10-6 M; [MU] 
(monuron): 10-6 M; [DU] (diuron): 10-6 M; PRL: prolactin; AdH: adenohypophysis. (45) 
 
Figure 14 shows the PRL release from rat PRLOMA cultures in the presence of ED chemical 
agents enumerated in our experimental protocol. All the examined compounds showed a 
significant stimulating effect on the release of PRL from PRLOMA cultures compared to that 
of the control. 
 
Figure 14 Effects of EDC on PRL release from rat PRLOMA cultures, in vitro 
mean (PRL level)±SE; The mean and SEM are calculated from n=12. Abbreviations: [dClB] (1,4-
dichlorobenzene): 0.1 ng/ml]; [mClB] (chlorobenzene mix): 0.1 ng/ml; [PU] (phenuron): 10-6 M; [MU] 
(monuron): 10-6 M; [DU] (diuron): 10-6 M; PRL: prolactin; AdH: adenohypophysis. All EDC groups differ 
significantly from the control (p<0.001) for basal release. (45) 
We also studied the effects of uron ED on NH cell culture models by measuring oxytocin and 
AVP release as membrane function markers. OT and AVP release are indicators for the 
monoamine activated receptor cycle of neurohypophysis cells. The changing of these 
mechanisms was investigated using phenylurea agents (Figure 15 and Figure 16). E activated 
OT release (Figure 15 A) was significantly suppressed by PU and DU. Figure 15 B shows the 
effects of phenylureas on NE activation. MU and DU significantly reduced the effect of NE. 
OT exocytosis induced by 5-HT is shown on Figure 15 C. The applied phenylurea agents caused 
only a modest change in OT release from the NH. In the case of HA, only the combination with 
DU reduced the OT release significantly as seen in Figure 15 D. Figure 15 E shows OT release 
triggered by DA and again, only the combination with DU decreased it significantly. 
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Figure 15 The effect of 10-6 M 
phenylureas on OT release from NH via 
10-6 M monoamine activated receptor 
functions 
 n=12; mean (ng OT/mg protein) ± standard 
deviation (SD); *p<0.01, **p<0.001; Abbreviations: 
OT: oxytocin; PU: phenuron, MU: monuron, DU: 
diuron, E: epinephrine, NE: norepinephrine, 5-HT: 
serotonin, HA: histamine, DA: dopamine (61) 
 
As to the AVP release, the E activation was modified significantly by PU, DU and MU (Figure 
16 A). NE induced AVP release (Figure 16 B) was reduced by PU and DU. The stimulatory 
effects of 5-HT on the AVP release from NH cells (Figure 16 C) were decreased by PU and 
MU, but increased by DU. In Figure 16 D, it can be seen that the HA induced AVP release was 
diminished by PU and DU. The DA receptor mediated AVP release (Figure 16 E) from NH was 
significantly suppressed by PU, MU and DU.  
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Figure 16 The effect of 10-6 M 
phenylureas on AVP release from NH via 
10-6 M monoamine activated receptor 
functions  
 n=10; mean (pg AVP/mg protein) ± SD; *p<0.01, 
**p<0.001; Abbreviations: AVP: 8-arginine 
vasopressin, PU: phenuron, MU: monuron, DU: 
diuron, E: epinephrine, NE: norepinephrine, 5-HT: 
serotonin, HA: histamine, DA: dopamine (61) 
 
The effects of polyhalogenated hydrocarbon chlorobenzenes (mClB, dClB) are particularly 
important in the determination of human toxicity potential in environmental toxicity studies. 
The endocrine effects of the duration of treatment and the exposure dose of the chlorobenzene 
mix were monitored by the ACTH release from the adenohypophysis into the blood serum 
collected from the in vivo rat treatment experiments (Figure 17) and from the supernatant 
medium of the in vitro AdH model (Figure 18). We also investigated whether the ClB mix 
modified the energy transfer (Mg2+-dependent ATPase activity) necessary for the hormone 
release (Figure 19). 
Our experiments revealed statistical differences between treated and untreated groups. In Figure 
17, the serum ACTH concentration of the absolute control groups was compared to that of the 
groups treated with 0.1, 1.0 and 10.0 μg/bw. kg ClB. The serum ACTH levels of the groups 
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treated with 0.1 μg/bw. kg mClB increased appreciably compared with the control group. In the 
serum, the hormone concentration increased significantly after treatment with 1.0 μg/bw. kg 
ClB. Notable differences were detected between the hormone secretions of the control groups 
and those of the 10.0 μg/bw. kg manipulated groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 ACTH concentration of rat 
serum after in vivo exposition to 
chlorobenzene mix. A: Experimental groups 
(n=10) exposed to 0.1 µg/bw. kg dose of ClB. B: 
Experimental groups exposed to 1.0 µg/bw. kg dose 
of ClB. C: Experimental groups exposed to 10.0 
µg/bw. kg dose of ClB. The asterisks indicate the 
statistically significant differences to control 
(p<0.001). ACTH: adrenocorticotropic hormone; 
ClB: chlorobenzene (62) 
As shown in Figure 18, the ACTH release from cultured adenohypophysis increased 
significantly depending upon the dose and the duration of exposure. The release of ACTH 
increased significantly as a consequence of in vivo 0.1 μg/bw. kg mClB treatment compared 
with the control. The hormone levels of the supernatant media in 1.0 μg/bw. kg ClB treated 
groups showed an increasing tendency. As depicted in Figure 18, the hormone levels in the 10.0 
μg/bw. kg ClB treated groups were elevated significantly compared with the control group.  
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Figure 18 ACTH release from 
adenohypophysis cell cultures after in 
vivo exposition of the rats to 
chlorobenzene mix. A: Experimental groups 
(n=10) exposed to 0.1 µg/bw. kg dose of ClB. B: 
Experimental groups exposed to 1.0 µg/bw. kg dose 
of ClB. C: Experimental groups exposed to 10.0 
µg/bw. kg dose of ClB. The asterisks indicate the 
statistically significant differences to control 
(p<0.001). ACTH: adrenocorticotropic hormone; 
ClB: chlorobenzene (62) 
 
 
As shown in Figure 19, Mg2+-ATPase activity was elevated significantly due to 0.1 μg/bw. kg 
mClB treatment compared with the control (100%). Notable enhancements were also observed 
in the enzyme activities after 1.0 μg/bw. kg and 10 μg/bw. kg ClB treatments.  
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Figure 19 The effects of in vivo subtoxic 
doses of chlorobenzene mix on Mg2+-
dependent ATPase activity in rats  
A: Experimental groups (n=10) exposed to 0.1 
µg/bw. kg dose of ClB. B: Experimental groups 
exposed to 1.0 µg/bw. kg dose of ClB. C: 
Experimental groups exposed to 10.0 µg/bw. kg dose 
of ClB. The asterisks indicate the statistically 
significant differences to control (P<0.001). (62) 
 
When studying the effects of ED, we also included the direct physical exposure to EMF and its 
action on membrane functions in connection to 2.2.b objective. As an environmental factor, we 
used EMF doses present in our daily life (low frequency, extreme low dose, chronic treatment, 
regular prions). The effects of of the EMF factors on the cell membrane were monitored by the 
β-adrenergic receptor cycle using in vitro red blood cell models after an in vivo exposure 
protocol. β-adrenergic receptor functions were monitored by measuring intracellular levels of 
the secondary messenger cAMP. 
The effects of in vivo ELF-EMF exposure were detected by the in vitro β-adrenoceptor 
functional model. The effect of 10 µT ELF-EMF in vivo treatment on the NE-activated and 
β-adrenoceptor mediated intracellular level of cAMP is depicted on Figure 20. Compared to the 
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untreated response of the adaptation period, the β-adrenoceptor mediated cAMP levels 
decreased (P < 0.001) during the ELF-EMF treatment (Figure 20). 
 
.  
Figure 20 Effects of in vivo ELF-EMF treatment (n=40) on the NE-activated β-
adrenoceptor function 
Mean NE-activated cAMP levels ± SEM during treatment period (wk 2-4). Reference lines represent mean 
cAMP (nmol/ml RBC SUSP) level at the adaptation period (wk 1) for baseline (lower) and NE-activation 
(upper). ELF: extremely low frequency and dose, EMF: electromagnetic field, NE: norepinephrine, base: 
baseline, cAMP: 3’-5’cyclic adenosine monophosphate, RBC: red blood cell, SUSP: suspension. *** indicates 
significant difference from NE-activated cAMP level at the adaptation (wk 1) with Type I error α=0.001. (63) 
 
Figure 21 shows the characterization of ELF-EMF treatment on NE-activated β-adrenoceptor 
functions in time. The effect of ELF-EMF was significant over time compared to the control 
group during weeks 3-5 measured in nmol cAMP/ml in RBC SUSP. The values of the control 
group did not change throughout the whole experiment (Figure 21) 
The cAMP level of subjects in the ELF-EMF treated group had a decrease in the treatment 
period, while there was an increase in the regeneration period (Figure 21). At the intercept of 
the two fitted linear pieces (wk 4), the mean cAMP level was 9.6 nmol/ml RBC SUSP in the 
treated group, which was 7.1 nmol/ml RBC SUSP less than that of the control group ( Figure 
21). As 60% of the variation of cAMP levels comes from individual characteristics of turkeys, 
only 40% is from within subject effects.  
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Figure 21 Effects of the complete ELF-EMF experiment on turkeys 
Result of piecewise linear mixed model. Dashed thick, black lines represent predicted means. Dashed dark grey 
lines show individual trajectories. + control (n=4), ᴑ treated (n=40) subjects, cAMP: 3’-5’cyclic adenosine 
monophosphate, NE: norepinephrine, nmol/ml: nmol cAMP/ml RBC SUSP, RBC: red blood cell, SUSP: 
suspension (63) 
 
The Reversible Nature of the Biological Experimental Model 
After the treatment with ELF-EMF, a major question was whether the biological system (NE-
activated β adrenergic receptor function) was capable of returning to the starting state. 
Furthermore, a relevant question was whether, and if so, how this capacity was modified during 
the treatment. For this reason, the NE-activated β-adrenoceptor function was investigated 
weekly, over the regeneration period. The alterations of the β-adrenoceptor function are 
demonstrated during the experimental period (adaptation, ELF-EMF treatment, regeneration) 
on Figure 21. The measured NE-activated levels of cAMP were in compliance with the normal 
parameters at the end of the adaptation period. The piecewise linear mixed model revealed a 
decreased effectiveness of β-adrenoceptors, as the NE-activated cAMP level was getting lower 
and lower during the treatment with ELF EMF. After the end of the ELF-EMF treatment, the 
β-adrenoceptor functions returned to the starting out state in 5 weeks. As mentioned above, the 
recovery (increase) of β-adrenoceptor functions in the treated group was slower in the 
regeneration period (slope of cAMP: 1.5 nmol/ml RBC SUSP) as compared to the rate of 
decrease during the treatment period (Figure 21). The treated group did not differ from the 
control at the end of the regeneration period.  
39 
 
5.Discussion, conclusions 
Objective 2.1.a 
Nowadays, the functioning of societies generates numerous environmental burdens that 
represent a high health risk. Physical and/or chemical and/or biological environmental 
conditions alter the adaptive potentials of living systems, including those of higher genera, 
resulting in disturbances in their operation (64). In humans, the development of a number of 
diseases may be induced by changes in environmental conditions (65), which force the 
functioning of the human body to change. Biological system functioning disturbances caused 
by short-term, weak environmental effects are classified as reversible „small disturbances” by 
environmental science. Acute, but strong environmental effects, however, can alter the 
biological structure suddenly by causing malfunctioning; these are called „structural 
disturbances” (66). When a physician detects the result of an environmental effect causing a 
small disturbance in the human body, rapid and easily curable (with appropriate treatment) 
forms may be faced (e.g. sterile inflammation, infection). Therefore, these are reversible life 
sustaining process shifts (i. e. local characteristic changes). However, chronic, subtoxic, very 
low dose environmental exposure (lasting a period of several years) may lead to structural 
disturbances (e.g. cancer, metabolic disorders, cardiovascular diseases, mental disorders) (67). 
When subjected to chronic exposure, the living system (human organism) initially enters a 
period that can be followed by chronic inflammatory processes and it already can be interpreted 
as disease; further presence of the exposure forces the biological pattern to change its structure 
(e.g. cell transformation), and the disruption of cell division may be the consequence. At this 
point benign cell proliferations can be found which are relatively easily detectable (e.g. as a 
tumor by diagnostic imaging). If the environmental effect continues to persist, the biological 
pattern that has already been structurally disturbed may respond by turning malignant. The 
system state cycle, when this process stabilizes, will result in a previously unknown, both 
structurally and functionally new system state (68). In medical practice, these are interpreted as 
fixations of malignant diseases (69). Environmental exposures are classified as physical (e.g. 
radiation) and/or chemical (e.g. agents) and/or biological (e.g. infectious) stressors. Humans, 
as the evolutionarily most complex organisms, respond by making a shift in their homeostatic 
regulation. The optimal homeostatic system for humans is the psycho-neuro-endocrine- 
immunity, which is interpreted as health. When the attraction range changes, i.e. the 
environmental condition of a person’s quality of life will be different, human adaptation 
patterns will also be modified, depending on the strength of the effectors and the duration of 
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the effect. From an environmental hygienic point of view, therefore, a new approach would be 
justified in medical practice as regards taking the medical history and in diagnostic approach.  
Environmental loads that cause homeostatic disturbances can be identified as homeostatic 
disruptor (HD) effects; among them endocrine disruptor (ED) effects can be also found. In 
accordance with this classification, I have formed psycho-neurodisruptors (PNDs) (e.g. 
psychotropic substances) and immunological disruptors (IDs) (e.g. allergens), as sub-classes 
with direct effect area characteristics.  
EDC can be found as pathogenic factors in endometriosis, obesity, type2 diabetes mellitus, 
cryptorchidism, male infertility, decreased testosterone levels, thyroid functional disorders, etc. 
Since the thyroid gland can also be viewed as a regulator of metabolic functions in the biological 
control of the human body, it is continuously exposed to environmental stressors (physical, 
chemical). In the elimination and neutralization of chemical agents, shifts in metabolic 
processes may generate inflammatory responses. Therefore, the demonstration of the thyroid 
autoimmune inflammatory processes (anti-TPO, anti-TG) has been proved useful for diagnostic 
purposes. Additionally, when medical case history is taken, environmental stressors are 
systematically displayed for working conditions, households, lifestyles, and so on, i.e. the 
possibility for contact contamination is explored (58). Results suggest (59) that thyroid 
carcinomas can be evaluated as irreversible structural disorders, the frequency of which has 
increased according to literature data in recent decades (70). However, according to further 
vertical studies (Table 2, 3) (58), all individuals with autoimmune inflammation and elevated 
anti-TG or anti-TPO levels continuously encountered an environmental stressor that can 
facilitate a malignant structural thyroid disorder. The increasing frequency of thyroid 
carcinomas may warrant screening for thyroid disease (by determining the possible effects of 
environmental risk factors and thyroid function tests complemented by autoimmune 
inflammatory factors: anti-TPO, anti-TG), similarly to the possible suggestion to evaluate the 
ED effects for breast cancer risk (71). 
Objective 2.1.b 
From the viewpoint of the ED effect, it is desirable to clarify the role of some effectors in the 
cell-transformation disorders by model experiments. For this purpose, an endocrine benign cell 
proliferation model was constructed with induced feed-back disturbance in rats. Specifically, 
adenohypophysis prolactinoma was induced by treatment with an estrogen mimetic for 26 
weeks, with weekly subcutaneous implantation (estrone-acetate / CAS registry number: 901-
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93-9, Sigma, Germany; 150 μg / bw. kg/week). The hormone release characteristics of the thus 
induced prolactinoma (PRLOMA) were studied. For this purpose, we have developed a model 
in which the functional response of endocrine cells already showing benign changes can be 
traced after direct and/or indirect environmental stimuli. The model was standardized by 
determining the relative frequency of PRL and ACTH producing cells in healthy 
adenohypophysis (AdH) cell cultures versus prolactinomas adenohypophysis (PRLOMA) 
cultures based on their IR hormone contents (result Fig 1, 6, 7, 8, 9, 10, table 4) (60). 
In the AdH model, PRL secretion was significantly lower than in the PRLOMA culture 
(controlAdH: 7.13 ± 0.04 ng PRL/mg protein; controlPRLOMA: 17.14 ± 0.02 ng PRL/mg protein). 
With regard to ACTH secretion, PRLOMA cells, again, showed a significantly elevated level 
(controlAdH: 1528.25 ± 6.14 pg ACTH/mg protein; controlPRLOMA: 2193.64 ± 1.92 pg ACTH/mg 
protein) in comparison to normal AdH cells. Adenohypophysis cells with non-malignant 
transformation certainly have different endocrine functions in the homeostatic system since 
their spontaneous release activity was different for ACTH and PRL. The ACTH release control 
cycle is described by "AND" function, and is under hypothalamic control; it is regulated by 
adrenocortical negative feedback. Biological cycles that can be described with the "AND" 
function are those essential for life (e.g. human hypothalamus-adenohypophysis-adrenal cortex 
axis functional disorders). The "OR" function-related control systems are not essential at the 
organizational level of the given individual (e.g. PRL), life functions can be maintained even 
in their absence. In the "OR" cycle it can be seen that PRL release is centrally controlled (brain) 
by DA. DA is a monoamine mediator that can modify AVP synthesis as well as release. The 
disturbance of the control processes of the "OR" cycle will affect the "AND" cycles. Chronic 
dysregulation of the "OR" cycle may lead to structural disturbance, e.g. cellular proliferation, 
which is sustained by the continuity of the feedback information (e.g. PRL release is induced 
by the continuous presence of estrogen receptor, which increases cell proliferation as a cellular 
level mechanism). 
In the endocrine regulatory system, we selected an attractor for functional stability assay, which 
was studied with activation and inhibition cycles for the given model cells (Fig 1). Activation 
was induced with AVP, which significantly increases ACTH release in healthy endocrine 
regulation (+ AVPAdH: 10220.88 ± 20.36), and is inhibited by corticosterone (B) (+ BAdH: 
1502.17 ± 3.25) (45). Studying the same control cycle with PRLOMA (+ AVPPRLOMA: 12674.50 
± 7.23; + BPRLOMA: 2155.50 ± 7.04), we found that the regulatory pattern persists but with 
slightly different ratios. The effects mediated by changes in hormone levels in the regulation 
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prevail in both healthy and PRLOMA cells. At the same time, the basic regulation of the 
adenohypophyseal-adrenocortical axis shows a shift in PRLOMA. This may be important for 
environmental hygienic reasons because it implies a shift in the regulation of essential 
functioning of the hypophyseal-adrenal axis, which, if further induced by, for example, 
environmental exposure, may enhance the regulatory disturbance (6). 
Objective 2.2.a 
The ED effect was modeled by indirect and direct load on AdH and PRLOMA cells with the 
aim of identifying primary and/or possibly secondary endocrine disrupting effects. When 
studying a direct effect, the action of the respective agent on endocrine function is investigated, 
and as a primary biological effect, the ED action may be determined for that substance. If an 
ED effect is detected where the primary effect is not endocrine in nature, but the response 
mechanism results in an endocrine disorder, then we talk about a secondary ED effect. I 
considered it important to create this subclassification because this way even additive effect 
spectra can be identified, which may have relevance in therapeutic practice (72). 
When studying the primary ED effect, we investigated the action of halogenated aromatic 
hydrocarbons on the exocytotic activity of the hypophysis cells. In the case of AdH cells, the 
subtoxic doses of 1,4-dichlorobenzene, hexachlorobenzene + 1,2,4-trichlorobenzene, 
phenuron, monuron and diuron agents in the functional model of ACTH release (Fig 1) did not 
significantly alter the basic and the AVP/corticosterone influenced ACTH release when 
compared to the control (Fig 11). However, in the AVP activated state, each agent showed a 
significant increase in ACTH release relative to the control level. When these tests were carried 
out on cells showing a transformation in their proliferating ability (PRLOMA) ( Fig 6, Fig. 12.), 
a difference was found in the baseline levels (with the exception of phenuron) compared to the 
controls, which was also seen in AVP stimulation inhibited by corticosterone, and was 
maintained in the AVP stimulated AdH cells. For the ED effect, this result shows that cell 
transformation has sensitized the cells and the system has become unstable, and no longer able 
to compensate for some effects with its own vital potential. In medical practice, this may be of 
importance as it may support the flipping of healthy state cycle cells from the already unstable 
(e.g. PRLOMA) state to a new system cycle, i.e. the malignant attractor (computed tumor) 
model. In the outlined in vitro model, a primary ED effect has been demonstrated for the 
functioning of healthy and benign adenohypophysis cells in an essential function of ACTH 
release. As regards non-essential prolactin production, different secreted hormone levels were 
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detected in the baseline interpretation of AdH versus PRLOMA cells (Table 4) (45). 
Compounds with ED activity disrupted PRL secretion in PRLOMA, but not in normal AdH 
cells (Figure 13, 14). 
According to in vivo data of mClB treatments, depending on the duration of treatment and the 
dosage, the amount of serum ACTH (Fig 17) increased; and this was in correlation with ACTH 
secretion of in vitro AdH cells after the same treatment and energy transfer /Mg2+-dependent 
ATPase / (Fig 18, 19). According to the coherence of the effects of independent in vitro and in 
vivo treatments, these compounds can be considered as primary ED agents (62).  
The neurohypophysis also plays an essential role in homeostasis. Our investigations were 
extended to uron agents for OT and AVP release functions in order to clarify further ED effects. 
(Our group clarified the effect of ClB on these hormone secretions earlier (52)). Our results 
(Fig 2) show that AVP release attractants activated by monoamines (epinephrine, 
norepinephrine, histamine, serotonin, dopamine) were significantly altered by uron compounds. 
With respect to OT release, basal release values were significantly altered only by phenuron 
when compared to control. However, in the case of different monoamine attractors, only 
monuron (containing a single chlorine substituent) did not deviate from the significant effects 
of the other agents. Monuron changed the activated state after the administration of 
norepinephrine significantly, and this phenomenon was not observed in the case of any other 
monoamines. The essential AVP regulatory processes in case of each monoamine activated 
AVP release attractor were altered by the members of the halogenated uron group, which makes 
these agents a clear primary ED factor (Fig. 15, 16)(61). The role of OT today is not considered 
to be essential in homeostasis – thus, after hypophysectomy, it is not routinely substituted, but 
its role in vasoconstriction, cerebral plasticity, immunomodulation, etc. (73) seems to be 
obvious, so it may be important for the organism to function optimally.  
Secondary ED effects were studied by simulating the isoforms. In this model, an indirect effect, 
which is caused by an environmental agent, was modeled by maintaining and shifting the 
physiological optimum in the ionic milieu. In this respect, our team has already studied the 
effects of potassium changes in the extracellular ionic milieu on hormone release (74). As a 
continuation of this, we investigated the effects of extracellular hypocalcemia on normal ADH 
and PRLOMA cells. When hypocalcaemia moves towards the physiological range, ACTH 
release approaches the control values in normal AdH cells (Figure 7). Release characteristics 
are still regulated for time and dose dependencies within the first 30 minutes, only after 60 
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minutes do extreme effects and exocytosis separate from each other. In PRLOMA, the time-
traced curves of the extracellular hypocalcemic characteristics of ACTH release (Figure 9) 
follow no particular order. As to prolactin release, AdH cells in calcium deprived milieu secrete 
normal quantities which were not compensated for their control range. As the dose of calcium 
approaches the physiological value, AdH cells present compensated prolactin secretion patterns 
(Figure 8). In PRLOMA, the hypocalcemia dose curves are time-decompressed (chaotic), 
compared to those of normal AdH cells (Figure 10)(60). It can be seen, that the changing 
environmental impacts can quickly shift PRLOMA cells from stability, as they cannot 
compensate for these changes. This also demonstrates that transformed cells characterized by a 
significant increase in their rate of division are not stable. In these cells, the cell attractor cannot 
adequately compensate for the shifted condition, which can be modeled and characterized by 
„AND” functions (conditions for maintaining isoosmosis, isoionia, isovolemia, etc.). 
Secondary ED effects may be pivotal because they are expressed through the extracellular 
parameter changes which are responsible for the homeostasis of the cells; these changes may 
generate more serious processes than it would be expected in unstable, diseased organisms. It 
is particularly important to keep in mind in the case of individuals whose ability to adapt is not 
yet, or no longer of a high potential (e.g. newborns, infants, aging organisms, etc.). In medical 
practice, therefore, it is essential to know about and to assess the risk of secondary ED effects.  
To accomplish this, databases need to be created; adequate data sources are available, e.g. 
electronic patient record system, but they should be structured in a big data system. Previously, 
the display and classification of primary and secondary ED agents with effect factors were not 
separated. The significance of this need has already been recognized, but its use not regularly 
seen in therapeutic practice. Our work presents an initial version, since according to the ISO 
14040 standard for Life Cycle Analysis (LCA), when determining human health potential, 
environmental factors must be standardized for 1,4-dichlorobenzene. This standard is also used 
to evaluate ecotoxicological events, which will greatly support extrapolation from animal 
experiments. The primary ED effects presented in this paper have already been reported, and 
are therefore classified as ED components. Based on the numeric data of the effect, it would be 
worth considering the effect of the standard compound as a unit, and relating the effect of other 
EDC to this value. This is what our group is working on at the moment. It would also be useful 
to do the same with secondary effects, specifying various „AND” systems.  
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Objective 2.2.b 
From an environmental hygienic point of view, we also wished to examine the role of physical 
environmental exposures in addition to EDC (75). Thus, our research also focuses on studying 
the role of EMF effects in neuroendocrine regulation. The EMF influences are present quite 
dominantly in societies through the use of electricity (transformation, transportation) (76) and 
via the operation of communication systems (77). The effects of electric fields can be warded 
off by electrostatic shielding (Faraday cage) (78), but this does not solve the problem of 
magnetic exposure factors (79). Its significance is different from that of EDC because the latter 
have a homeostatic compensating mechanism (organ, organ system, buffer system, etc.) which, 
for example, provides adaptation in humans. It is probable that the attraction range 
(environmental conditions) can be described by „AND” function modified biological patterns. 
For this reason, only those living attractors were able to survive which were able to operate 
compensatory mechanisms (regulatory cascades) with thresholds (80). No organic regulation 
to compensate for the effects of magnetic field ever developed in biological evolution. It can 
therefore be assumed that in the environment that constitutes the background for evolution, no 
changes have occurred that may have disrupted the life functions of the biological material (81). 
There is no homeostatic mechanism (no magnetic organ) for the present living biological 
material patterns (for organisms on Earth) to compensate for the magnetic field induced effect. 
Society, as the present evolutionary scene, uses such magnetic field modifying technical and 
technological tools which generate these changes continuously. The behavior of electrically-
charged structures and charged molecules changes (82) in the magnetic field, which, if it affects 
the living organism, generates threshold-dependent but safe state changes. In the present theses, 
we investigated the mechanism of norepinephrine activation, which is of significance in 
neuroendocrine regulation. The NE membrane receptor acts on a specific activation pathway as 
an agonist, via the cAMP messenger system. The transduction process starting with the NE + 
receptor binding from the extracellular space on the β-adrenoceptor, it highly depends on the 
activation (83) and integrity of the membrane (84), the membrane potential (85), the rate of 
movement of the receptor subunits (86) and its direction (87).  
Since the mentioned physical parameters (potential, velocity, displacement) are vector 
quantities, the changes in the force fields that are experimentally simulated by the EMF effect, 
can generate changes in the outlined events. These can only be detected when they are threshold 
effects at the level of a particular mechanism. Our results show that the β-adrenoceptor function 
was disrupted by in vivo EMF treatment (Fig 20), which resulted in a marked decrease of 
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receptor activity. When the treatments were suspended, we observed that the induced direct 
and/or indirect ED effect was still apparent as a minor disorder. All this was confirmed by the 
appearance of regeneration (Fig 21), as the investigated monoamine activated attractor returned 
to its stable (control) state. In our further course of our work we also continue to investigate the 
monoamine receptor involved in the OT and AVP release in the experimental model presented. 
In this regard, we can evaluate the results as an indirect ED effect. However, monoamines also 
have a direct ED effect due to their hormone-like properties. In another context, we can say that 
as there is no direct body and/or regulatory system for adaptation to EMF effects, these effects 
can only be interpreted as indirect (63). 
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6. Summary 
1. 
Exploring the pathomechanisms of health problems that emerge from exposure to ED factors 
is significant in the diagnostic and therapeutic practice as well. Therefore, it is important to 
thematically explore possible ED exposure (occupational, residential, lifestyle, electrical 
appliances/devices in the apartment and the living environment, the workplace and its 
environment) when taking medical history, and the recommendations of the Endocrine 
Societies should certainly be complemented with them. Among the biochemical parameters, 
when exposure to ED is high, it seems to be desirable to measure the amount of anti-TG and/or 
anti-TPO in the serum. Compared to the ATA and ETA results, all malignant thyroid tumour 
(follicular cell origin) patients, whom I examined, and had been exposed to ED, all of them had 
elevated levels of anti-TG and/or anti-TPO. Accordingly, chronic ED exposure may be a 
causative factor in triggering malignant effects via autoimmune inflammatory processes.  
When characterization and classification of ED factors are accessible on a broader scale, 
preventive solutions may reduce the risk of developing and progressing endocrine disorders. 
(Objective 2.1.a) 
2. 
Our benign pituitary PRLOMA model was experimentally generated in rats. ED that stimulate 
structural changes similar to those seen in our model all cause cell transformation disturbances 
(e.g. estrogen mimetics). We managed to standardize a model which enables one to study 
chronic ED effects in addition to the triggering ED effects in benign endocrine disorders, which 
can be examined according to the requirements of the Boolean network algorithms. (Objective 
2.1.b) 
3. 
It has been proven that the AVP-induced ACTH release attractor is shifted both in AdH and 
PRLOMA, which enhances regulating disturbance in PRLOMA. When these two models are 
further burdened with ED exposures classified as primary (direct) and/or secondary (indirect) 
ED factors, the PRLOMA becomes more unstable because it cannot present the compensatory 
mechanisms characteristic for a healthy state cycle. Due to its regulatory instability in the 
presence of EDC agents in subtoxic doses, PRLOMA may easily migrate into a new system 
cycle. It was found that both uron compounds (phenuron, monuron, diuron) and chlorobenzenes 
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(1,2,4-trichloro-benzene+hexachlorobenzene=1:1; 1,4-dichlorobenzene) have a primary ED 
effect on PRL and ACTH release of both the healthy adenohypophysis and the one with 
prolactinoma. The primary ED effect of the uron agents was also verified by following the 
regulatory attractor of monoamine (DA, NE, E, 5-HT, HA) activated OT, AVP secretion of 
neurohypophysis cells. Those EDC effects which do not interfere with the endocrinium directly, 
but through disruption of one of the „AND” functions (in our case, ionic milieu - Ca2+) can be 
viewed as secondary ED activities. Regulatory behavior of PRLOMA also has a higher degree 
of instability toward secondary EDC effects compared to healthy AdH. (Objective 2.2.a) 
4. 
Biological effects caused by EDC factors are standardized relative to the effects of 1,4-
dichlorobenzene by the ISO 14040 standard packet, which prefers lifecycle studies, eco-
toxicological potential (ETP) and human toxicity potential (HTP). We conducted the study of 
the known standard effect in our work accordingly, and we consider it important to measure 
and record the effect(s) for a significant EDC in various endocrine disorders. (Objective 2.2.a) 
5. 
In addition to the ED-induced effects of the chemical agents, we also began to clarify the ED 
role of physical factors. The effects of ELF-EMF (as a factor) were studied in vivo. We found 
that the functional activity of the cell membrane was significantly altered by the use of extreme 
low dose electromagnetic radiation by a chronic treatment scheme. In our research system, the 
receptor-agonist/antagonist attractor (endocrine regulation cycle) was set up as a test model, 
similarly to the previous hypophysis release models. The EMF effect can be labeled as an ED 
factor for all beta-receptor-linked hormone releases. The reversibility test model of the ELF-
EMF was also developed, which could provide important information in the design of the 
planned data system due to the strength and periods of its effect. (Objective 2.2.b) 
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